Oxfendazole: a promising agent for the treatment and control of helminth infections in humans

Armando E. Gonzalez, Ellen E. Codd, John Horton, Hector H. Garcia, Robert H. Gilman

Research output: Contribution to journalScientific reviewpeer-review

28 Scopus citations


© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Oxfendazole (methyl [5-(phenylsulphinyl)-1H benzimidazole-2-yl] carbamate) has a particularly long metabolic half-life in ruminants, and its metabolite fenbendazole also has anthelminthic action. A very limited number of drugs are available for the treatment of some zoonotic helminth infections, such as neurocysticercosis and echinococcosis. More recent work has expanded oxfendazole’s nonclinical safety profile and demonstrated its safety and bioavailability in healthy human volunteers, thus advancing the possibility of a new and greatly needed option for antiparasitic treatment of geohelminths and tissue parasites. Areas covered: The present article reviews evidence supporting the safety and efficacy of oxfendazole against both gut and tissue dwelling helminths in animals, as well as more recent safety and pharmacokinetic data supporting its potential for use in human parasitoses. Expert commentary: The pharmacokinetics, safety, and wide spectrum of efficacy of oxfendazole are consistently demonstrated in intestinal helminth infections of animals as well as in tissue dwelling larval cestode and trematode infections in diverse animal species. Now supported by first-in-human safety and pharmacokinetic data, oxfendazole becomes a promising alternative to the limited portfolio of antiparasitic drugs available to treat helminthic diseases of humans.
Original languageAmerican English
Pages (from-to)51-56
Number of pages6
JournalExpert Review of Anti-Infective Therapy
StatePublished - 2 Jan 2019


Dive into the research topics of 'Oxfendazole: a promising agent for the treatment and control of helminth infections in humans'. Together they form a unique fingerprint.

Cite this